Praxis Precision Medicines, Inc. (PRAX)

NASDAQ: PRAX · IEX Real-Time Price · USD
3.93
+0.65 (19.82%)
Aug 8, 2022 4:00 PM EDT - Market closed
19.82%
Market Cap 178.86M
Revenue (ttm) n/a
Net Income (ttm) -208.41M
Shares Out 45.51M
EPS (ttm) -4.72
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,023,585
Open 3.34
Previous Close 3.28
Day's Range 3.33 - 3.94
52-Week Range 1.63 - 23.56
Beta n/a
Analysts Buy
Price Target 9.18 (+133.6%)
Earnings Date Aug 15, 2022

About PRAX

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential... [Read more...]

Industry Biotechnology
IPO Date Oct 16, 2020
Employees 139
Stock Exchange NASDAQ
Ticker Symbol PRAX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for PRAX stock is "Buy." The 12-month stock price forecast is 9.18, which is an increase of 133.59% from the latest price.

Price Target
$9.18
(133.59% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2022 Financial Results

PRAX-944 Phase 2b Essential1 Study topline results expected in 4Q22; primary endpoint updated to efficacy

Praxis Precision Medicines to Present at 2022 Wedbush PacGrow Healthcare Conference

BOSTON, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for c...

Praxis (PRAX) Tanks on Negative Data From Depression Study

Praxis (PRAX) posts negative data from the phase II/III Aria study that evaluated PRAX-114 for monotherapy treatment of major depressive disorder. Shares fall.

Praxis Precision Medicines (PRAX) Stock Plummets on Disappointing Study Results

PRAX stock is taking a beating on Monday after Praxis Precision Medicines released results from a recent clinical trial. The post Praxis Precision Medicines (PRAX) Stock Plummets on Disappointing Study ...

Praxis Precision Posts Disappointing Data From Depression Study

Praxis Precision Medicines Inc's (NASDAQ: PRAX) Phase 2/3 Aria Study of PRAX-114 for major depressive disorder (MDD) did not achieve statistical significance on the primary endpoint. The primary endpoin...

Praxis Precision Medicines Reports Negative Results from PRAX-114 Phase 2/3 Monotherapy Aria Study in Patients with M...

Aria Study did not achieve statistical significance on the primary endpoint

Praxis Precision Medicines Adds Global Business Expertise to Board of Directors with Appointment of Jill DeSimone

BOSTON, May 23, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for ce...

Praxis Precision Medicines to Present at Upcoming Investor Conferences

BOSTON, May 11, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for ce...

Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2022 Financial Results

PRAX-944 demonstrated clinically meaningful functional improvement in essential tremor patients in Part B of Phase 2a study

Praxis Precision Medicines Reports Positive Topline Results from PRAX-944 Phase 2a Study in Essential Tremor Patients

PRAX-944 demonstrated clinically meaningful functional improvement in essential tremor patients in Part B of Phase 2a study

Praxis Precision Medicines to Provide Corporate Update and Report First Quarter 2022 Financial Results on Monday, May...

BOSTON, May 02, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for ce...

Praxis Precision Medicines Showcases Largest Targeted Epilepsy Portfolio in Industry at 2022 Epilepsy Day

Live event in New York City and webcast to start at 8:30 a.m. ET Live event in New York City and webcast to start at 8:30 a.m. ET

Praxis Precision Medicines to Host Epilepsy Day on April 27, 2022

BOSTON, April 13, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for ...

Praxis Precision Medicines to Present Data from PRAX-944 for Essential Tremor at 2022 American Academy of Neurology A...

BOSTON, April 01, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for ...

Praxis Precision Medicines to Present at Stifel's 4th Annual CNS Day

BOSTON, March 21, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for ...

Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results

PRAX-114 Phase 2/3 monotherapy MDD Aria Study topline results expected in June 2022

12 biotech stocks to consider buying now as prospects for the sector brighten this year

Biotechnology is so beaten down, relative valuation metrics suggest some stocks could more than double

Praxis Precision Medicines to Host Movement Disorder Day on December 17, 2021

BOSTON, Dec. 10, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for c...

Praxis Precision Medicines Announces Management Team Appointments

BOSTON, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for c...

Praxis Precision Medicines to Present at Piper Sandler's 33rd Annual Virtual Healthcare Conference

BOSTON, Nov. 24, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for c...

Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2021 Financial Results

Enrollment on track for 1H22 topline results for PRAX-114 Phase 2/3 monotherapy MDD Aria Study and for PRAX-114 Phase 2 dose-ranging MDD Acapella Study

Praxis Precision Medicines To Provide Corporate Update And Report Third Quarter 2021 Financial Results On Wednesday, ...

BOSTON, Oct. 22, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for c...

Praxis Precision Medicines to Present at Citi's 16th Annual BioPharma Virtual Conference

CAMBRIDGE, Mass., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of ther...

BofA Initiates Praxis Precision Medical At Buy

Praxis Precision Medicines Inc's (NASDAQ:PRAX) lead asset has demonstrated encouraging data for central nervous system diseases and has a broad pipeline that targets both prevalent and rare disorders, a...

Praxis Unveils Perimenopausal Depression Trial Data

Praxis Precision Medicines Inc (NASDAQ: PRAX) has reported results from its PRAX-114 Phase 2a Part B proof-of-concept trial for perimenopausal depression (PMD). PRAX-114 60 mg suspension formulation (n=...